Drugs / PT005
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00893971 | May → Jul 2009 | — | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT00880490 | Nov 2008 → May 2009 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | Met primary |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT01587079 | Apr → Sep 2012 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01349868 | May → Jul 2011 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01085045 | Mar → Nov 2010 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-09-16 | AstraZeneca | Results The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease astrazeneca.com ↗
The incidence of adjudicated pneumonia was low and comparable in all treatment arms. |
| 2015-03-18 | AstraZeneca | Results AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD astrazeneca.com ↗
Both PT001 and PT005 also demonstrated statistically significant improvements in trough FEV1 compared to placebo. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PT005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01085045 ↗ |
| Known as | Formoterol Fumarate | “Formoterol Fumarate 12 mcg (Foradil Aerolizer)” NCT00880490 ↗ |
| Action | Activate | “Formoterol fumarate (FF) is a well-established long-acting β2-agonist.” PMID 25060541 ↗ Jul 2014 |
| Route | Inhaled | “single dose, inhaled” NCT00880490 ↗ |